Cargando…
The efficacy of oxaliplatin, surufatinib, and camrelizumab on neuroendocrine carcinoma: a case report and literature review
BACKGROUND: Extra-pulmonary neuroendocrine carcinomas (EP-NECs) are rare, accounting for ~1/100,000 of NECs, aggressive neoplasms and poor prognosis. Sometimes, a non-neuroendocrine component is also accompanying these EP-NECs. Curative surgery is suggested for early stage patients while system chem...
Autores principales: | Wang, Xianhua, Hu, Shaobo, Su, Fei, Lin, Jie, Duan, Jianghui, Tan, Haidong, Tan, Huangying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761152/ https://www.ncbi.nlm.nih.gov/pubmed/36544653 http://dx.doi.org/10.21037/atm-22-4789 |
Ejemplares similares
-
Current treatments and future potential of surufatinib in
neuroendocrine tumors (NETs)
por: Xu, Jianming
Publicado: (2021) -
Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis
por: Cai, Tianying, et al.
Publicado: (2023) -
Surufatinib-induced renal thrombotic microangiopathy: first case report and review of literature
por: Zhu, Wenjiao, et al.
Publicado: (2023) -
Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies
por: Li, J., et al.
Publicado: (2022) -
Rare malignant insulinoma with multiple liver metastases derived from ectopic pancreas: 3-year follow-up and literature review
por: Liu, Qing, et al.
Publicado: (2018)